Paul E Verweij

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6511466/publications.pdf

Version: 2024-02-01

491 papers	33,470 citations	3515 90 h-index	6113 159 g-index
500 all docs	500 docs citations	500 times ranked	16762 citing authors

#	Article	IF	Citations
1	ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clinical Microbiology and Infection, 2022, 28, 222-238.	2.8	103
2	Managing secondary fungal infections in severe COVID-19: how to move forward?. Lancet Respiratory Medicine,the, 2022, 10, 127-128.	5.2	6
3	Meanderella rijsii, a new opportunist in the fungal order Pleosporales. Microbes and Infection, 2022, 24, 104932.	1.0	1
4	A 67-Year-Old Male Patient With COVID-19ÂWith Worsening Respiratory Function and Acute Kidney Failure. Chest, 2022, 161, e5-e11.	0.4	6
5	Regional Impact of COVID-19-Associated Pulmonary Aspergillosis (CAPA) during the First Wave. Journal of Fungi (Basel, Switzerland), 2022, 8, 96.	1.5	8
6	Management of drugâ€"drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. Lancet Haematology,the, 2022, 9, e58-e72.	2.2	29
7	Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance. Emerging Microbes and Infections, 2022, 11, 703-714.	3.0	22
8	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, , .	1.3	1
9	Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. Clinical Microbiology and Infection, 2022, 28, 1003-1009.	2.8	8
10	Inappropriate use of ivermectin during the COVID-19 pandemic: Primum non nocere!. Clinical Microbiology and Infection, 2022, , .	2.8	7
11	Absence of candidemia in critically ill patients with COVID-19 receiving selective digestive decontamination. Intensive Care Medicine, 2022, 48, 611-612.	3.9	5
12	Tackling the emerging threat of antifungal resistance to human health. Nature Reviews Microbiology, 2022, 20, 557-571.	13.6	311
13	Use of Bulk Segregant Analysis for Determining the Genetic Basis of Azole Resistance in the Opportunistic Pathogen Aspergillus fumigatus. Frontiers in Cellular and Infection Microbiology, 2022, 12, 841138.	1.8	6
14	Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSAâ€FLU study. Mycoses, 2022, 65, 656-660.	1.8	3
15	Differential Functions of Individual Transcription Factor Binding Sites in the Tandem Repeats Found in Clinically Relevant cyp51A Promoters in Aspergillus fumigatus. MBio, 2022, 13, e0070222.	1.8	7
16	Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. Journal of Antimicrobial Chemotherapy, 2022, 77, 2053-2073.	1.3	27
17	Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. Journal of Antimicrobial Chemotherapy, 2022, 77, 2217-2226.	1.3	4
18	Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study. , 2022, 4, e0696.		9

#	Article	IF	Citations
19	Triazole-resistant Aspergillus luchuensis, an industrially important black Aspergillus spp. used in fermentation in East Asia, isolated from the patient with invasive pulmonary aspergillosis in China. Emerging Microbes and Infections, 2022, , 1-9.	3.0	7
20	Phylogenomic Analysis of a 55.1-kb 19-Gene Dataset Resolves a MonophyleticFusariumthat Includes theFusarium solaniSpecies Complex. Phytopathology, 2021, 111, 1064-1079.	1.1	107
21	The Challenge of Managing COVID-19 Associated Pulmonary Aspergillosis. Clinical Infectious Diseases, 2021, 73, e3615-e3616.	2.9	9
22	Ventilator-associated pneumonia involving Aspergillus flavus in a patient with coronavirus disease 2019 (COVID-19) from Argentina. Medical Mycology Case Reports, 2021, 31, 19-23.	0.7	31
23	Fungal infections should be part of the core outcome set for COVID-19. Lancet Infectious Diseases, The, 2021, 21, e145.	4.6	8
24	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	4.6	586
25	Regional Differences in Antifungal Susceptibility of the Prevalent Dermatophyte Trichophyton rubrum. Mycopathologia, 2021, 186, 53-70.	1.3	11
26	Dynamics of Aspergillus fumigatus in Azole Fungicide-Containing Plant Waste in the Netherlands (2016â€“2017). Applied and Environmental Microbiology, 2021, 87, .	1.4	20
27	Genetic and Phenotypic Characterization of in-Host Developed Azole-Resistant Aspergillus flavus Isolates. Journal of Fungi (Basel, Switzerland), 2021, 7, 164.	1.5	3
28	Defining Galactomannan Positivity in the Updated EORTC/MSGERC Consensus Definitions of Invasive Fungal Diseases. Clinical Infectious Diseases, 2021, 72, S89-S94.	2.9	28
29	ISO standard 20776-1 or serial 2-fold dilution for antifungal susceptibility plate preparation: that is the question!. Journal of Antimicrobial Chemotherapy, 2021, 76, 1793-1799.	1.3	6
30	Proven Aspergillus flavus pulmonary aspergillosis in a COVIDâ€19 patient: A case report and review of the literature. Mycoses, 2021, 64, 809-816.	1.8	17
31	Chlorhexidine for the Treatment of Fusarium Keratitis: A Case Series and Mini Review. Journal of Fungi (Basel, Switzerland), 2021, 7, 255.	1.5	3
32	Identifying Conserved Generic Aspergillus spp. Co-Expressed Gene Modules Associated with Germination Using Cross-Platform and Cross-Species Transcriptomics. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 217	1.5	0
33	Triazole-Resistance in Environmental Aspergillus fumigatus in Latin American and African Countries. Journal of Fungi (Basel, Switzerland), 2021, 7, 292.	1.5	16
34	Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells. JCI Insight, 2021, 6, .	2.3	33
35	A worldâ€wide analysis of reduced sensitivity to <scp>DMI</scp> fungicides in the banana pathogen Pseudocercospora fijiensis. Pest Management Science, 2021, 77, 3273-3288.	1.7	8
36	Potency of Olorofim (F901318) Compared to Contemporary Antifungal Agents against Clinical Aspergillus fumigatus Isolates and Review of Azole Resistance Phenotype and Genotype Epidemiology in China. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	13

#	Article	IF	Citations
37	Selective Flamingo Medium for the Isolation of Aspergillus fumigatus. Microorganisms, 2021, 9, 1155.	1.6	3
38	Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. Cell Reports Medicine, 2021, 2, 100289.	3.3	15
39	Implementation of rapid diagnostics assays for detection of histoplasmosis and cryptococcosis in central american people living with HIV. Mycoses, 2021, 64, 1396-1401.	1.8	11
40	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Medicine, 2021, 47, 674-686.	3.9	49
41	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine, 2021, 47, 819-834.	3.9	106
42	Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis â€“ Authors' reply. Lancet Infectious Diseases, The, 2021, 21, 767-769.	4.6	5
43	Front Cover Image, Volume 77, Issue 7. Pest Management Science, 2021, 77, i.	1.7	0
44	Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Eurosurveillance, 2021, 26, .	3.9	55
45	A mould infection in disguise. Clinical Microbiology and Infection, 2021, 27, 854-855.	2.8	2
46	Azole-Resistance Development; How the Aspergillus fumigatus Lifecycle Defines the Potential for Adaptation. Journal of Fungi (Basel, Switzerland), 2021, 7, 599.	1.5	11
47	COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. Lancet Respiratory Medicine,the, 2021, 9, 795-802.	5.2	56
48	Antifungal Susceptibility and Mutations in the Squalene Epoxidase Gene in Dermatophytes of the Trichophyton mentagrophytes Species Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0005621.	1.4	49
49	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. Lancet Infectious Diseases, The, 2021, 21, e364-e374.	4.6	99
50	Invasive pulmonary aspergillosis associated with viral pneumonitis. Current Opinion in Microbiology, 2021, 62, 21-27.	2.3	39
51	Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients. Journal of Clinical Microbiology, 2021, 59, e0122921.	1.8	50
52	When to change treatment of acute invasive aspergillosis: an expert viewpoint. Journal of Antimicrobial Chemotherapy, 2021, 77, 16-23.	1.3	15
53	Stable prevalence of triazole-resistance in Aspergillus fumigatus complex clinical isolates in a Belgian tertiary care center from 2016 to 2020. Journal of Infection and Chemotherapy, 2021, 27, 1774-1778.	0.8	6
54	Fungal keratitis caused by Pseudallescheria boydii: clinical and mycological characteristics. Journal of Ophthalmic Inflammation and Infection, 2021, 11, 30.	1.2	1

#	Article	IF	Citations
55	Aspergillus fumigatus tryptophan metabolic route differently affects host immunity. Cell Reports, 2021, 34, 108673.	2.9	16
56	Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease. Intensive Care Medicine, 2021, 47, 1343-1344.	3.9	0
57	Multinational Observational Cohort Study of COVID-19â€"Associated Pulmonary Aspergillosis1. Emerging Infectious Diseases, 2021, 27, 2892-2898.	2.0	82
58	Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi. Journal of Fungi (Basel, Switzerland), 2021, 7, 909.	1.5	29
59	Flower Bulb Waste Material is a Natural Niche for the Sexual Cycle in Aspergillus fumigatus. Frontiers in Cellular and Infection Microbiology, 2021, 11, 785157.	1.8	3
60	Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. Clinical Infectious Diseases, 2020, 70, 349-350.	2.9	20
61	Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Medical Mycology, 2020, 58, 444-452.	0.3	50
62	Highâ€dose posaconazole for azoleâ€resistant aspergillosis and other difficultâ€toâ€treat mould infections. Mycoses, 2020, 63, 122-130.	1.8	35
63	High Azole Resistance in Aspergillus fumigatus Isolates from Strawberry Fields, China, 2018. Emerging Infectious Diseases, 2020, 26, 81-89.	2.0	37
64	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	2.9	1,429
65	Does Pulmonary Aspergillosis Complicate Coronavirus Disease 2019?. , 2020, 2, e0211.		10
66	Reply to Fekkar et al.: Fungal Infection during COVID-19: Does Aspergillus Mean Secondary Invasive Aspergillosis?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 903-904.	2.5	5
67	A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology. Journal of Fungi (Basel, Switzerland), 2020, 6, 274.	1.5	7
68	Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIVâ€"A Case Report from Argentina and Literature Review. Journal of Fungi (Basel, Switzerland), 2020, 6, 275.	1.5	41
69	The Medical Triazole Voriconazole Can Select for Tandem Repeat Variations in Azole-Resistant Aspergillus Fumigatus Harboring TR34/L98H Via Asexual Reproduction. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock	1.5	10
70	The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda. Fungal Biology Reviews, 2020, 34, 202-214.	1.9	68
71	Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. European Respiratory Journal, 2020, 56, 2002554.	3.1	98
72	No to Neocosmospora : Phylogenomic and Practical Reasons for Continued Inclusion of the Fusarium solani Species Complex in the Genus Fusarium. MSphere, 2020, 5, .	1.3	61

#	Article	IF	Citations
73	Contact lens-related fungal keratitis. Lancet Infectious Diseases, The, 2020, 20, 1100.	4.6	5
74	Update on Matrix-Assisted Laser Desorption Ionizationâ€"Time of Flight Mass Spectrometry Identification of Filamentous Fungi. Journal of Clinical Microbiology, 2020, 58, .	1.8	31
75	Parasexual recombination enablesAspergillus fumigatusto persist in cystic fibrosis. ERJ Open Research, 2020, 6, 00020-2020.	1.1	18
76	First Case of Rhinocerebral Mucormycosis Caused by Lichtheimia ornata, with a Review of Lichtheimia Infections. Mycopathologia, 2020, 185, 555-567.	1.3	18
77	Hmg1 Gene Mutation Prevalence in Triazole-Resistant Aspergillus fumigatus Clinical Isolates. Journal of Fungi (Basel, Switzerland), 2020, 6, 227.	1.5	12
78	Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe, The, 2020, 1, e53-e55.	3.4	158
79	COVID-19â€"associated Pulmonary Aspergillosis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 132-135.	2.5	286
80	InvasiveAspergillusTracheobronchitis Emerging as a Highly Lethal Complication of Severe Influenza. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 646-648.	2.5	13
81	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	3.9	278
82	Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013â€"2018. Emerging Infectious Diseases, 2020, 26, 1447-1455.	2.0	46
83	Evaluation of a New Culture Protocol for Enhancing Fungal Detection Rates in Respiratory Samples of Cystic Fibrosis Patients. Journal of Fungi (Basel, Switzerland), 2020, 6, 82.	1.5	9
84	Mycotic Infections in Free-Ranging Harbor Porpoises (Phocoena phocoena). Frontiers in Marine Science, 2020, 7, .	1.2	6
85	In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates. Journal of Antimicrobial Chemotherapy, 2020, 75, 2582-2586.	1.3	5
86	European confederation of medical mycology expert consultâ€"An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	1.8	8
87	International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe. Critical Care, 2020, 24, 84.	2.5	27
88	Aspergillus fumigatus and pan-azole resistance: who should be concerned?. Current Opinion in Infectious Diseases, 2020, 33, 290-297.	1.3	54
89	Clinical relevance of Scedosporium spp. and Exophiala dermatitidis in patients with cystic fibrosis: A nationwide study. Medical Mycology, 2020, 58, 859-866.	0.3	16
90	Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for In Vitro Antifungal Susceptibility Testing of Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	11

#	Article	IF	Citations
91	Implications for IV posaconazole dosing in the era of obesity. Journal of Antimicrobial Chemotherapy, 2020, 75, 1006-1013.	1.3	18
92	Reply to Mafaciolli and Pasqualotto. Clinical Infectious Diseases, 2020, 71, 2542-2543.	2.9	2
93	Molecular Mechanisms of Conidial Germination in Aspergillus spp. Microbiology and Molecular Biology Reviews, 2020, 84, .	2.9	68
94	Pharmacokinetics and Pharmacodynamics of Posaconazole. Drugs, 2020, 80, 671-695.	4.9	80
95	Surveillance of catheter-related bloodstream infections in haemato-oncology patients: comparison of two definitions. Journal of Hospital Infection, 2020, 105, 686-690.	1.4	1
96	Epidemiology and Clinical Management of Fusarium keratitis in the Netherlands, 2005â€"2016. Frontiers in Cellular and Infection Microbiology, 2020, 10, 133.	1.8	27
97	Burden of serious fungal infections in the Netherlands. Mycoses, 2020, 63, 625-631.	1.8	23
98	Antifungal Activity of Antimicrobial Peptides and Proteins against Aspergillus fumigatus. Journal of Fungi (Basel, Switzerland), 2020, 6, 65.	1.5	15
99	Aspergillus fumigatus-specific antibodies in patients with chronic tuberculosis. International Journal of Tuberculosis and Lung Disease, 2020, 24, 853-856.	0.6	2
100	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) â€" a multicenter study. Open Forum Infectious Diseases, 2020, 7, S795-S796.	0.4	0
101	Diagnostic-driven management of invasive fungal disease in hematology in the era of prophylaxis and resistance emergence: Dutch courage?. Medical Mycology, 2019, 57, S267-S273.	0.3	1
102	Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi. Fungal Genetics and Biology, 2019, 132, 103254.	0.9	51
103	ECMM CandiRegâ€"A ready to use platform for outbreaks and epidemiological studies. Mycoses, 2019, 62, 920-927.	1.8	19
104	A Comparison of Isolation Methods for Black Fungi Degrading Aromatic Toxins. Mycopathologia, 2019, 184, 653-660.	1.3	11
105	External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify Candida auris. Journal of Fungi (Basel, Switzerland), 2019, 5, 94.	1.5	11
106	cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	17
107	The fading boundaries between patient and environmental routes of triazole resistance selection in Aspergillus fumigatus. PLoS Pathogens, 2019, 15, e1007858.	2.1	41
108	Environmental Hotspots for Azole Resistance Selection of Aspergillus fumigatus, the Netherlands. Emerging Infectious Diseases, 2019, 25, 1347-1353.	2.0	95

#	Article	IF	Citations
109	Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 2759-2766.	1.3	52
110	Recreation of in-host acquired single nucleotide polymorphisms by CRISPR-Cas9 reveals an uncharacterised gene playing a role in Aspergillus fumigatus azole resistance via a non-cyp51A mediated resistance mechanism. Fungal Genetics and Biology, 2019, 130, 98-106.	0.9	25
111	Raw genome sequence data for 13 isogenic Aspergillus fumigatus strains isolated over a 2 year period from a patient with chronic granulomatous disease. Data in Brief, 2019, 25, 104021.	0.5	8
112	In Vitro Activity of Chlorhexidine Compared with Seven Antifungal Agents against 98 Fusarium Isolates Recovered from Fungal Keratitis Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	24
113	Aspergillosis related to severe influenza: A worldwide phenomenon?. Clinical Respiratory Journal, 2019, 13, 540-542.	0.6	10
114	Aerosol Transmission of Aspergillus fumigatus in Cystic Fibrosis Patients in the Netherlands. Emerging Infectious Diseases, 2019, 25, 797-799.	2.0	33
115	Nontuberculous mycobacterial pulmonary disease and Aspergillus co-infection: Bonnie and Clyde?. European Respiratory Journal, 2019, 54, 1900117.	3.1	13
116	Relevance of heterokaryosis for adaptation and azole-resistance development in Aspergillus fumigatus. Proceedings of the Royal Society B: Biological Sciences, 2019, 286, 20182886.	1.2	15
117	Triazole Antifungal Susceptibility Patterns among Aspergillus Species in QuÃ©bec, Canada. Journal of Clinical Microbiology, 2019, 57, .	1.8	3
118	Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clinical Microbiology and Infection, 2019, 25, 799-806.	2.8	128
119	2268. Clinical Implications of Azole-Resistant vs. Azole-Susceptible Invasive Aspergillosis in Hematological Malignancy (CLARITY): A Multicenter Study. Open Forum Infectious Diseases, 2019, 6, S776-S776.	0.4	0
120	In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent ofÂinvasive aspergillosis. Journal of Infection and Chemotherapy, 2019, 25, 157-160.	0.8	16
121	Trends in Azole Resistance in Aspergillus fumigatus, the Netherlands, 1994â€"2016. Emerging Infectious Diseases, 2019, 25, 176-178.	2.0	51
122	Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device. Journal of Clinical Microbiology, 2019, 57, .	1.8	21
123	Phenotypic plasticity and the evolution of azole resistance in Aspergillus fumigatus; an expression profile of clinical isolates upon exposure to itraconazole. BMC Genomics, 2019, 20, 28.	1.2	24
124	How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates. Clinical Microbiology and Infection, 2019, 25, 681-687.	2.8	59
125	Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients â€" A Dutch, multicentre study. Journal of Cystic Fibrosis, 2019, 18, 221-226.	0.3	55
126	Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study. Clinical Infectious Diseases, 2019, 68, 1463-1471.	2.9	189

#	Article	IF	Citations
127	Epidemiology of Aspergillus species causing keratitis in Mexico. Mycoses, 2019, 62, 144-151.	1.8	25
128	Elevated MIC Values of Imidazole Drugs against Aspergillus fumigatus Isolates with TR ₃₄ /L98H/S297T/F495I Mutation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	38
129	Fusarium metavorans sp. nov.: The frequent opportunist â€˜FSSC6â€™. Medical Mycology, 2018, 56, S144-S152.	0.3	15
130	Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1389-1394.	1.3	30
131	Gene co-expression analysis identifies gene clusters associated with isotropic and polarized growth in Aspergillus fumigatus conidia. Fungal Genetics and Biology, 2018, 116, 62-72.	0.9	37
132	The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azoleâ€resistance. A nationwide survey and rationale for the <scp>DB</scp>â€<scp>MSG</scp> 002 study protocol. Mycoses, 2018, 61, 656-664.	1.8	26
133	Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection, 2018, 24, e1-e38.	2.8	942
134	In-host microevolution of Aspergillus fumigatus: A phenotypic and genotypic analysis. Fungal Genetics and Biology, 2018, 113, 1-13.	0.9	80
135	Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
136	Triazole resistance surveillance in Aspergillus fumigatus. Medical Mycology, 2018, 56, S83-S92.	0.3	114
137	Current antifungal treatment of fusariosis. International Journal of Antimicrobial Agents, 2018, 51, 326-332.	1.1	83
138	Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. Journal of Antimicrobial Chemotherapy, 2018, 73, 134-142.	1.3	29
139	Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. Clinical Pharmacokinetics, 2018, 57, 267-286.	1.6	55
140	Genotyping of Aspergillus fumigatus in Formalin-Fixed Paraffin-Embedded Tissues and Serum Samples From Patients With Invasive Aspergillosis. Frontiers in Cellular and Infection Microbiology, 2018, 8, 377.	1.8	5
141	Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. Current Opinion in Infectious Diseases, 2018, 31, 471-480.	1.3	133
142	Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates. Journal of Fungi (Basel, Switzerland), 2018, 4, 103.	1.5	38
143	Antifungal Use in Veterinary Practice and Emergence of Resistance. , 2018, , 359-402.		6
144	Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respiratory Medicine,the, 2018, 6, 782-792.	5.2	638

#	Article	IF	Citations
145	Molecular Detection of Azole-Resistant Aspergillus fumigatus in Clinical Samples. Frontiers in Microbiology, 2018, 9, 515.	1.5	34
146	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	1.4	81
147	Discovery and characterization of novel Aspergillus fumigatus mycoviruses. PLoS ONE, 2018, 13, e0200511.	1.1	43
148	Epidemiology and aetiologies of cryptococcal meningitis in Africa, 1950â€"2017: protocol for a systematic review. BMJ Open, 2018, 8, e020654.	0.8	20
149	Absent inÂvitro interaction between chloroquine and antifungals against Aspergillus fumigatus. Clinical Microbiology and Infection, 2017, 23, 679-681.	2.8	1
150	Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. Clinical Pharmacokinetics, 2017, 56, 1197-1206.	1.6	27
151	Fever and arthralgia after â€˜volcano boardingâ€™ in Nicaragua. Travel Medicine and Infectious Disease, 2017, 16, 68-69.	1.5	2
152	Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	31
153	Personalized medicine in influenza. Current Opinion in Pulmonary Medicine, 2017, 23, 237-240.	1.2	3
154	In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	5
155	Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	24
156	In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates. Journal of Antimicrobial Chemotherapy, 2017, 72, 2548-2552.	1.3	78
157	Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole. Medical Mycology Case Reports, 2017, 16, 16-19.	0.7	20
158	Influenza-associated Aspergillosis in Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 524-527.	2.5	176
159	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999â€"2015. Clinical Infectious Diseases, 2017, 65, 216-225.	2.9	50
160	In Vitro Antifungal Susceptibility Profiles of 12 Antifungal Drugs against 55 Trichophyton schoenleinii Isolates from Tinea Capitis Favosa Patients in Iran, Turkey, and China. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	17
161	Itraconazole or Amphotericin B for Talaromycosis. New England Journal of Medicine, 2017, 377, 1402-1403.	13.9	4
162	Animal Models for Studying Triazole Resistance in Aspergillus fumigatus. Journal of Infectious Diseases, 2017, 216, S466-S473.	1.9	14

#	Article	IF	Citations
163	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy, 2017, 72, 3325-3333.	1.3	39
164	Single-Center Evaluation of an Agar-Based Screening for Azole Resistance in Aspergillus fumigatus by Using VIPcheck. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	38
165	Evolution of cross-resistance to medical triazoles inAspergillus fumigatusthrough selection pressure of environmental fungicides. Proceedings of the Royal Society B: Biological Sciences, 2017, 284, 20170635.	1.2	51
166	Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the Cryptococcus Genus. MSphere, 2017, 2, .	1.3	124
167	Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	17
168	Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit. Journal of Clinical Microbiology, 2017, 55, 3210-3218.	1.8	56
169	Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China. Emerging Microbes and Infections, 2017, 6, 1-6.	3.0	26
170	A Novel Environmental Azole Resistance Mutation in Aspergillus fumigatus and a Possible Role of Sexual Reproduction in Its Emergence. MBio, 2017, 8, .	1.8	104
171	Spectrophotometric reading of EUCAST antifungal susceptibility testing of Aspergillus fumigatus. Clinical Microbiology and Infection, 2017, 23, 98-103.	2.8	18
172	Evaluation of MIC Strip Isavuconazole Test for Susceptibility Testing of Wild-Type and Non-Wild-Type Aspergillus fumigatus Isolates. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	15
173	Systemic Antifungal Agents: Current Status and Projected Future Developments. Methods in Molecular Biology, 2017, 1508, 107-139.	0.4	42
174	Antifungal Susceptibility Testing of Fusarium: A Practical Approach. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 T	1.5	49
175	Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications. , 2017, , 403-421.		5
176	Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis. Journal of Medical Microbiology, 2017, 66, 898-904.	0.7	27
177	Azole Resistance ofAspergillus fumigatusin Immunocompromised Patients with Invasive Aspergillosis. Emerging Infectious Diseases, 2016, 22, 158-159.	2.0	27
178	Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses, 2016, 59, 101-107.	1.8	36
179	Decreased Cell Wall Galactosaminogalactan inAspergillus nidulansMediates Dysregulated Inflammation in the Chronic Granulomatous Disease Host. Journal of Interferon and Cytokine Research, 2016, 36, 488-498.	0.5	18
180	Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20150460.	1.8	243

#	Article	IF	Citations
181	Voriconazole-Susceptible and Voriconazole-Resistant Aspergillus fumigatus Coinfection. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 927-929.	2.5	35
182	Are the TR ₄₆ /Y121F/T289A Mutations in Azole-Resistant Aspergillosis Patient Acquired or Environmental?. Antimicrobial Agents and Chemotherapy, 2016, 60, 3259-3260.	1.4	12
183	Optimizing antifungal strategies to improve patient survival. Future Microbiology, 2016, 11, 1211-1215.	1.0	4
184	Epidemiology and Molecular Characterizations of Azole Resistance in Clinical and Environmental Aspergillus fumigatus Isolates from China. Antimicrobial Agents and Chemotherapy, 2016, 60, 5878-5884.	1.4	62
185	Azole resistance surveillance inAspergillus fumigatus: beneficial or biased?. Journal of Antimicrobial Chemotherapy, 2016, 71, 2079-2082.	1.3	49
186	In-host adaptation and acquired triazole resistance in Aspergillus fumigatus : a dilemma for clinical management. Lancet Infectious Diseases, The, 2016, 16, e251-e260.	4.6	123
187	Discrimination of Aspergillosis, Mucormycosis, Fusariosis, and Scedosporiosis in Formalin-Fixed Paraffin-Embedded Tissue Specimens by Use of Multiple Real-Time Quantitative PCR Assays. Journal of Clinical Microbiology, 2016, 54, 2798-2803.	1.8	68
188	Next-Generation Sequencing in the Mycology Lab. Current Fungal Infection Reports, 2016, 10, 37-42.	0.9	40
189	Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 2346-2351.	1.4	20
190	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. Clinical Pharmacokinetics, 2016, 55, 723-733.	1.6	35
191	Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR ₃₄ /L98H- and TR ₄₆ /Y121F/T289A-Positive Aspergillus fumigatus Isolates Obtained from Patients in Iran from 2010 to 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 387-392.	1.4	23
192	Azole Resistance inAspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?. Clinical Infectious Diseases, 2016, 62, 362-368.	2.9	468
193	Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013. Eurosurveillance, 2016, 21, .	3.9	59
194	In vitro antifungal susceptibility of Trichophyton violaceum isolated from tinea capitis patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1072-1075.	1.3	10
195	Asexual sporulation facilitates adaptation: The emergence of azole resistance inAspergillus fumigatus. Evolution; International Journal of Organic Evolution, 2015, 69, 2573-2586.	1.1	35
196	The Strength of Synergistic Interaction between Posaconazole and Caspofungin Depends on the Underlying Azole Resistance Mechanism of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2015, 59, 1738-1744.	1.4	25
197	First Description of Azole-Resistant Aspergillus fumigatus Due to TR ₄₆ /Y121F/T289A Mutation in France. Antimicrobial Agents and Chemotherapy, 2015, 59, 4331-4335.	1.4	61
198	Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. Expert Review of Anti-Infective Therapy, 2015, 13, 9-27.	2.0	37

#	Article	IF	Citations
199	Genotypeâ€"phenotype complexity of the TR46/Y121F/T289A cyp51A azole resistance mechanism in Aspergillus fumigatus. Fungal Genetics and Biology, 2015, 82, 129-135.	0.9	91
200	De novo induction of resistance against voriconazole in Aspergillus fumigatus. Journal of Global Antimicrobial Resistance, 2015, 3, 52-53.	0.9	1
201	Neglected fungal zoonoses: hidden threats to man and animals. Clinical Microbiology and Infection, 2015, 21, 416-425.	2.8	54
202	High-Level Pan-Azole-Resistant Aspergillosis. Journal of Clinical Microbiology, 2015, 53, 2343-2345.	1.8	20
203	Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 4403-4409.	1.4	48
204	Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model. Antimicrobial Agents and Chemotherapy, 2015, 59, 2855-2866.	1.4	60
205	Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 1487-1494.	1.4	22
206	Prospective Multicenter International Surveillance of Azole Resistance inAspergillus fumigatus. Emerging Infectious Diseases, 2015, 21, 1041-1044.	2.0	302
207	Multiâ€triazoleâ€resistant Aspergillus fumigatus infections in Australia. Mycoses, 2015, 58, 350-355.	1.8	89
208	Emergence of fusarioses in a university hospital in Turkey during a 20-year period. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1683-1691.	1.3	36
209	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	6.5	262
210	Aspergillusand aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. Medical Mycology, 2015, 53, 765-797.	0.3	172
211	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authors' response. Journal of Antimicrobial Chemotherapy, 2015, 70, 634-635.	1.3	4
212	Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands. Journal of Antimicrobial Chemotherapy, 2015, 70, 178-181.	1.3	81
213	Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications. , 2015, , 1-17.		2
214	Occurrence of azole-resistant species of Aspergillus in the UK environment. Journal of Global Antimicrobial Resistance, 2014, 2, 276-279.	0.9	51
215	Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. Journal of Antimicrobial Chemotherapy, 2014, 69, 2979-2983.	1.3	122
216	Intrapulmonary Posaconazole Penetration at the Infection Site in an Immunosuppressed Murine Model of Invasive Pulmonary Aspergillosis Receiving Oral Prophylactic Regimens. Antimicrobial Agents and Chemotherapy, 2014, 58, 2964-2967.	1.4	13

#	Article	IF	Citations
217	Antifungal Susceptibility Patterns of Opportunistic Fungi in the Genera Verruconis and Ochroconis. Antimicrobial Agents and Chemotherapy, 2014, 58, 3285-3292.	1.4	26
218	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2014, 69, 1611-1619.	1.3	28
219	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clinical Microbiology and Infection, 2014, 20, 47-75.	2.8	262
220	Susceptibility Breakpoints for Amphotericin B and Aspergillus Species in an In Vitro Pharmacokinetic-Pharmacodynamic Model Simulating Free-Drug Concentrations in Human Serum. Antimicrobial Agents and Chemotherapy, 2014, 58, 2356-2362.	1.4	16
221	Incidence of and risk factors for persistent gram-positive bacteraemia and catheter-related thrombosis in haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2014, 49, 264-269.	1.3	15
222	Pharmacokinetics of caspofungin in ICU patients. Journal of Antimicrobial Chemotherapy, 2014, 69, 3294-3299.	1.3	61
223	Black Yeasts and Their Filamentous Relatives: Principles of Pathogenesis and Host Defense. Clinical Microbiology Reviews, 2014, 27, 527-542.	5.7	94
224	The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside. Drug Resistance Updates, 2014, 17, 37-50.	6.5	89
225	Screening of the central nervous system in children with invasive pulmonary aspergillosis. Medical Mycology Case Reports, 2014, 4, 8-11.	0.7	14
226	Continuous Infusion of Amphotericin B Deoxycholate for the Treatment of Life-Threatening Candida Infections. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1033-1033.	2.5	2
227	Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Review of Anti-Infective Therapy, 2013, 11, 931-941.	2.0	65
228	Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus. Pest Management Science, 2013, 69, 165-170.	1.7	56
229	Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles. Clinical Infectious Diseases, 2013, 57, 513-520.	2.9	308
230	Inhibitory and Fungicidal Effects of Antifungal Drugs against Aspergillus Species in the Presence of Serum. Antimicrobial Agents and Chemotherapy, 2013, 57, 1625-1631.	1.4	21
231	Azole-ResistantAspergillus fumigatus, Iran. Emerging Infectious Diseases, 2013, 19, 832-834.	2.0	58
232	In Vitro Interaction of Voriconazole and Anidulafungin against Triazole-Resistant Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2013, 57, 796-803.	1.4	35
233	Pharmacodynamics and Dose-Response Relationships of Liposomal Amphotericin B against Different Azole-Resistant Aspergillus fumigatus Isolates in a Murine Model of Disseminated Aspergillosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1866-1871.	1.4	38
234	Azole resistance in Aspergillus fumigatus. Current Opinion in Infectious Diseases, 2013, 26, 493-500.	1.3	175

#	Article	IF	Citations
235	Amphotericin B- and Voriconazole-Echinocandin Combinations against Aspergillus spp.: Effect of Serum on Inhibitory and Fungicidal Interactions. Antimicrobial Agents and Chemotherapy, 2013, 57, 4656-4663.	1.4	32
236	Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. Journal of Antimicrobial Chemotherapy, 2013, 68, 385-393.	1.3	60
237	Invasive Fungal Infections in Patients with Chronic Granulomatous Disease. Advances in Experimental Medicine and Biology, 2013, 764, 27-55.	0.8	82
238	Favorable Outcome of Neonatal Cerebrospinal Fluid Shunt-Associated Candida Meningitis with Caspofungin. Antimicrobial Agents and Chemotherapy, 2013, 57, 2391-2393.	1.4	12
239	Pharmacodynamics of Anidulafungin against Clinical Aspergillus fumigatus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 303-308.	1.4	16
240	Update on Antifungal Resistance in Children. Pediatric Infectious Disease Journal, 2013, 32, 556-557.	1.1	3
241	Composite Survival Index to Compare Virulence Changes in Azole-Resistant Aspergillus fumigatus Clinical Isolates. PLoS ONE, 2013, 8, e72280.	1.1	20
242	Epidemiological Cutoff Values for Azoles and Aspergillus fumigatus Based on a Novel Mathematical Approach Incorporating cyp51A Sequence Analysis. Antimicrobial Agents and Chemotherapy, 2012, 56, 2524-2529.	1.4	36
243	Aspergillus nidulans and Chronic Granulomatous Disease: A Unique Hostâ€"Pathogen Interaction. Journal of Infectious Diseases, 2012, 206, 1128-1137.	1.9	84
244	Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species. Antimicrobial Agents and Chemotherapy, 2012, 56, 2635-2642.	1.4	244
245	Extensive Genetic Diversity within the Dutch Clinical Cryptococcus neoformans Population. Journal of Clinical Microbiology, 2012, 50, 1918-1926.	1.8	53
246	Molecular Epidemiology of Aspergillus fumigatus Isolates Harboring the TR ₃₄ /L98H Azole Resistance Mechanism. Journal of Clinical Microbiology, 2012, 50, 2674-2680.	1.8	127
247	ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clinical Microbiology and Infection, 2012, 18, 53-67.	2.8	280
248	Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 887-888, 79-84.	1.2	41
249	ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clinical Microbiology and Infection, 2012, 18, 1-8.	2.8	91
250	ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clinical Microbiology and Infection, 2012, 18, 9-18.	2.8	310
251	ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clinical Microbiology and Infection, 2012, 18, 19-37.	2.8	977
252	ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. Clinical Microbiology and Infection, 2012, 18, 38-52.	2.8	264

#	Article	IF	Citations
253	ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clinical Microbiology and Infection, 2012, 18, 68-77.	2.8	81
254	Importance of neutropenia for development of invasive infections at various phases of treatment for hemato-oncological diseases in children. Scandinavian Journal of Infectious Diseases, 2012, 44, 355-362.	1.5	5
255	Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus. PLoS ONE, 2012, 7, e31801.	1.1	320
256	Favorable outcome of chronic disseminated candidiasis in four pediatric patients with hematological malignancies. Medical Mycology, 2012, 50, 315-319.	0.3	6
257	Rapid Induction of Multiple Resistance Mechanisms in Aspergillus fumigatus during Azole Therapy: a Case Study and Review of the Literature. Antimicrobial Agents and Chemotherapy, 2012, 56, 10-16.	1.4	205
258	Discovery of a hapE Mutation That Causes Azole Resistance in Aspergillus fumigatus through Whole Genome Sequencing and Sexual Crossing. PLoS ONE, 2012, 7, e50034.	1.1	168
259	Aspergillusspecies intrinsically resistant to antifungal agents. Medical Mycology, 2011, 49, S82-S89.	0.3	138
260	Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. Current Opinion in Pharmacology, 2011, 11, 486-493.	1.7	16
261	The structureâ€"function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: The mechanism of L98H azole resistance. Fungal Genetics and Biology, 2011, 48, 1062-1070.	0.9	92
262	Clinical Implications of Azole Resistance inAspergillus fumigatus, the Netherlands, 2007â€"2009. Emerging Infectious Diseases, 2011, 17, 1846-1854.	2.0	381
263	PULMONARY ASPERGILLOSIS CAUSED BY A PAN-AZOLE-RESISTANT ASPERGILLUS FUMIGATUS IN A 10-YEAR-OLD BOY. Pediatric Infectious Disease Journal, 2011, 30, 268-270.	1.1	12
264	Performance of the new Platelia Candida Plus assays for the diagnosis of invasive Candida infection in patients undergoing myeloablative therapy. Medical Mycology, 2011, 49, 848-855.	0.3	21
265	Impact of Therapeutic Drug Monitoring of Voriconazole in a Pediatric Population. Pediatric Infectious Disease Journal, 2011, 30, 533-534.	1.1	42
266	European expert opinion on the management of invasive candidiasis in adults. Clinical Microbiology and Infection, 2011, 17, 1-12.	2.8	113
267	Calcineurin-dependent galactomannan release in Aspergillus fumigatus. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 551-553.	1.3	3
268	Hospital point-of-use water filtration to prevent exposure to waterborne pathogens. BMC Proceedings, 2011, 5, .	1.8	0
269	Aspergillus fumigatus cell wall components differentially modulate host TLR2 and TLR4 responses. Microbes and Infection, 2011, 13, 151-159.	1.0	93
270	Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?. Future Microbiology, 2011, 6, 335-347.	1.0	90

#	Article	IF	Citations
271	Failure of Posaconazole Therapy in a Renal Transplant Patient with Invasive Aspergillosis Due to Aspergillus fumigatus with Attenuated Susceptibility to Posaconazole. Antimicrobial Agents and Chemotherapy, 2011, 55, 3564-3566.	1.4	35
272	Comment on: Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. Journal of Antimicrobial Chemotherapy, 2011, 66, 954-955.	1.3	8
273	Human Leukocytes Kill Aspergillus nidulans by Reactive Oxygen Species-Independent Mechanisms. Infection and Immunity, 2011, 79, 767-773.	1.0	43
274	A SÃ©zary cryptogram. Disseminated cryptococcal infection. Netherlands Journal of Medicine, 2011, 69, 346, 349.	0.6	0
275	Genetic Variation of Innate Immune Genes in HIV-Infected African Patients With or Without Oropharyngeal Candidiasis. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 87-94.	0.9	48
276	Point-of-use filtration method for the prevention of fungal contamination of hospital water. Journal of Hospital Infection, 2010, 76, 56-59.	1.4	23
277	Development of Azole Resistance in Aspergillus fumigatus during Azole Therapy Associated with Change in Virulence. PLoS ONE, 2010, 5, e10080.	1.1	143
278	Rapid Diagnosis of Azole-Resistant Aspergillosis by Direct PCR Using Tissue Specimens. Journal of Clinical Microbiology, 2010, 48, 1478-1480.	1.8	56
279	Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis. Antimicrobial Agents and Chemotherapy, 2010, 54, 4758-4764.	1.4	80
280	Acute Cardiac Failure due to Intra-Atrial Mass Caused by Zygomycetes in an Immunocompromised Paediatric Patient. Case Reports in Medicine, 2010, 2010, 1-5.	0.3	5
281	Identification ofPaecilomyces variotiiin Clinical Samples and Settings. Journal of Clinical Microbiology, 2010, 48, 2754-2761.	1.8	101
282	Azole Resistance Profile of Amino Acid Changes in Aspergillus fumigatus CYP51A Based on Protein Homology Modeling. Antimicrobial Agents and Chemotherapy, 2010, 54, 2425-2430.	1.4	166
283	Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene. Antimicrobial Agents and Chemotherapy, 2010, 54, 860-865.	1.4	110
284	Opportunistic and systemic fungi. , 2010, , 1823-1852.		2
285	Multiple-azole-resistantAspergillus fumigatusosteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Medical Mycology, 2009, 47, 217-220.	0.3	141
286	Moulds: diagnosis and treatment. Journal of Antimicrobial Chemotherapy, 2009, 63, i31-i35.	1.3	2
287	Timing and Dose of Tissue Plasminogen Activator to Prevent Abscess Formation After Surgical Treatment of Secondary Peritonitis in the Rat. Surgical Innovation, 2009, 16, 299-305.	0.4	2
288	Azoleâ€Resistant Central Nervous System Aspergillosis. Clinical Infectious Diseases, 2009, 48, 1111-1113.	2.9	80

#	Article	IF	Citations
289	In VitroAntifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries. Journal of Chemotherapy, 2009, 21, 272-281.	0.7	58
290	Possible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles. Applied and Environmental Microbiology, 2009, 75, 4053-4057.	1.4	390
291	Tissue-type plasminogen activator prevents abscess formation but does not affect healing of bowel anastomoses and laparotomy wounds in rats with secondary peritonitis. Surgery, 2009, 146, 939-946.	1.0	5
292	Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clinical Microbiology and Infection, 2009, 15, 380-386.	2.8	29
293	Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clinical Microbiology and Infection, 2009, 15, 625-633.	2.8	75
294	Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints. Drug Resistance Updates, 2009, 12, 141-147.	6.5	222
295	Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis. Medical Mycology, 2009, 47, 802-807.	0.3	9
296	Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents. Clinical Infectious Diseases, 2009, 48, 1441-1458.	2.9	368
297	International Interlaboratory Proficiency Testing Program for Measurement of Azole Antifungal Plasma Concentrations. Antimicrobial Agents and Chemotherapy, 2009, 53, 303-305.	1.4	56
298	Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagnostic Microbiology and Infectious Disease, 2009, 64, 408-415.	0.8	30
299	Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infectious Diseases, The, 2009, 9, 789-795.	4.6	524
300	Fatal consequences of an ear infection. Lancet, The, 2009, 373, 1658.	6.3	3
301	5-Flucytosine. , 2009, , 307-315.		0
302	Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2008, 51, 423-426.	0.8	12
303	Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis. British Journal of Surgery, 2008, 95, 1287-1293.	0.1	6
304	Evaluation of Cytotoxic, Genotoxic and CYP450 Enzymatic Competition Effects of Tanzanian Plant Extracts Traditionally Used for Treatment of Fungal Infections. Basic and Clinical Pharmacology and Toxicology, 2008, 102, 515-526.	1.2	27
305	Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiology, 2008, 8, 135.	1.3	70
306	Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat. Surgery, 2008, 144, 66-73.	1.0	8

#	Article	IF	Citations
307	Amphotericin B-deoxycholate overdose due to administration error in pediatric patients. Medical Mycology, 2008, 46, 185-187.	0.3	7
308	In Vitro Activities at pH 5.0 and pH 7.0 and In Vivo Efficacy of Flucytosine against Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 2008, 52, 4483-4485.	1.4	26
309	Pseudomonas aeruginosaas a Cause of 1,3â€Î²â€<scp>d</scp>â€Glucan Assay Reactivity. Clinical Infectious Diseases, 2008, 46, 1930-1931.	2.9	122
310	Improved Detection of Circulating Aspergillus Antigen by Use of a Modified Pretreatment Procedure. Journal of Clinical Microbiology, 2008, 46, 1391-1397.	1.8	19
311	Drosomycin-Like Defensin, a Human Homologue ofDrosophila melanogasterDrosomycin with Antifungal Activity. Antimicrobial Agents and Chemotherapy, 2008, 52, 1407-1412.	1.4	32
312	Singleâ€Dose Fluconazole versus Standard 2â€Week Therapy for Oropharyngeal Candidiasis in HIVâ€Infected Patients: A Randomized, Doubleâ€Blind, Doubleâ€Dummy Trial. Clinical Infectious Diseases, 2008, 47, 1270-1276.	2.9	37
313	Aspergillus calidoustus sp. nov., Causative Agent of Human Infections Previously Assigned to Aspergillus ustus. Eukaryotic Cell, 2008, 7, 630-638.	3.4	114
314	Gastrointestinal zygomycosis due toRhizopus microsporusvar.rhizopodiformisas a manifestation of chronic granulomatous disease. Medical Mycology, 2008, 46, 491-494.	0.3	18
315	Therapeutic Drug Monitoring of Voriconazole. Therapeutic Drug Monitoring, 2008, 30, 403-411.	1.0	116
316	Brine Shrimp Toxicity Evaluation Of Some Tanzanian Plants Used Traditionally For The Treatment Of Fungal Infections. Tropical Journal of Obstetrics and Gynaecology, 2008, 4, 219-25.	0.3	29
317	Emericellaquadrilineataas Cause of Invasive Aspergillosis. Emerging Infectious Diseases, 2008, 14, 566-572.	2.0	55
318	Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism. PLoS Medicine, 2008, 5, e219.	3.9	630
319	Optimization of the Cutoff Value for the Aspergillus Double-Sandwich Enzyme Immunoassay. Clinical Infectious Diseases, 2007, 44, 1329-1336.	2.9	163
320	Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. Journal of Antimicrobial Chemotherapy, 2007, 60, 385-393.	1.3	15
321	Halo Sign and Improved Outcome. Clinical Infectious Diseases, 2007, 44, 1666-1667.	2.9	17
322	Reply to Miceli and Anaissie. Clinical Infectious Diseases, 2007, 44, 760-761.	2.9	4
323	Aspergillosisâ€”and a misleading sensitivity result. Lancet, The, 2007, 370, 102.	6.3	33
324	Aspergillus species identification in the clinical setting. Studies in Mycology, 2007, 59, 39-46.	4.5	236

#	Article	IF	Citations
325	A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations. Antimicrobial Agents and Chemotherapy, 2007, 51, 1897-1904.	1.4	443
326	Multiple-Triazoleâ€"Resistant Aspergillosis. New England Journal of Medicine, 2007, 356, 1481-1483.	13.9	360
327	A colorimetric and spectrophotometric method forin vitrosusceptibility testing ofAspergillusspecies against caspofungin. Medical Mycology, 2007, 45, 351-355.	0.3	7
328	Activity and post antifungal effect of chlorpromazine and trifluopherazine against Aspergillus, Scedosporium and zygomycetes. Mycoses, 2007, 50, 270-276.	1.8	23
329	Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model. International Journal of Colorectal Disease, 2007, 22, 819-825.	1.0	7
330	The Role of Conventional Diagnostic Tools. , 2007, , 19-40.		0
331	Alternaria infectoriaphaeohyphomycosis in a renal transplant patient. Medical Mycology, 2006, 44, 379-382.	0.3	22
332	Nonâ€"Culture-Based Diagnostics for Opportunistic Fungi. Infectious Disease Clinics of North America, 2006, 20, 711-727.	1.9	74
333	The concentration-dependent nature of in vitro amphotericin Bâ€"itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. International Journal of Antimicrobial Agents, 2006, 28, 439-449.	1.1	28
334	Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. Journal of Ethnopharmacology, 2006, 108, 124-132.	2.0	142
335	Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health, 2006, 6, 12.	0.8	80
336	Legionella pneumophilain commercial bottled mineral water. FEMS Immunology and Medical Microbiology, 2006, 47, 42-44.	2.7	7
337	A peritonitis model with low mortality and persisting intra-abdominal abscesses. International Journal of Experimental Pathology, 2006, 87, 361-368.	0.6	20
338	Involvement of glycosaminoglycans in the attachment of pneumococci to nasopharyngeal epithelial cells. Microbes and Infection, 2006, 8, 316-322.	1.0	45
339	Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. Annals of Hematology, 2006, 85, 621-623.	0.8	32
340	Molecular diagnosis of invasive aspergillosis: the long and winding road. Future Microbiology, 2006, 1, 283-293.	1.0	19
341	Issues with galactomannan testing. Medical Mycology, 2006, 44, 179-183.	0.3	41
342	1,3-Î²-D-Glucan in Patients Receiving Intravenous Amoxicillinâ€"Clavulanic Acid. New England Journal of Medicine, 2006, 354, 2834-2835.	13.9	105

#	Article	IF	Citations
343	In Vitro Release by Aspergillus fumigatus of Galactofuranose Antigens, 1,3-Â-D-Glucan, and DNA, Surrogate Markers Used for Diagnosis of Invasive Aspergillosis. Journal of Clinical Microbiology, 2006, 44, 1711-1718.	1.8	67
344	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	2.9	3
345	Paradoxical Increase in CirculatingAspergillusAntigen during Treatment with Caspofungin in a Patient with Pulmonary Aspergillosis. Clinical Infectious Diseases, 2006, 43, e23-e25.	2.9	48
346	Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. European Cytokine Network, 2006, 17, 29-34.	1.1	125
347	Comparison of Visual 24-Hour and Spectrophotometric 48-Hour MICs to CLSI Reference Microdilution MICs of Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Candida spp.: a Collaborative Study. Journal of Clinical Microbiology, 2005, 43, 4535-4540.	1.8	33
348	Bifidobacterial Lipoglycan as a New Cause for False-Positive Platelia Aspergillus Enzyme-Linked Immunosorbent Assay Reactivity. Journal of Clinical Microbiology, 2005, 43, 3925-3931.	1.8	90
349	Efficacy and Pharmacodynamics of Flucytosine Monotherapy in a Nonneutropenic Murine Model of Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy, 2005, 49, 4220-4226.	1.4	25
350	Successful Treatment ofFusarium Keratitis with Cornea Transplantation and Topical and Systemic Voriconazole. Clinical Infectious Diseases, 2005, 40, e110-e112.	2.9	73
351	Influence of endogenous pro-inflammatory cytokines on neutrophil-mediated damage ofCandida albicanspseudohyphae, quantified in a modified tetrazolium dye assay. Medical Mycology, 2005, 43, 551-557.	0.3	10
352	International and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and Voriconazole. Journal of Clinical Microbiology, 2005, 43, 3884-3889.	1.8	120
353	Duration of antibiotic treatment: are even numbers odd?. Journal of Antimicrobial Chemotherapy, 2005, 56, 441-442.	1.3	5
354	Relationship between In Vitro Activities of Amphotericin B and Flucytosine and pH for Clinical Yeast and Mold Isolates. Antimicrobial Agents and Chemotherapy, 2005, 49, 3341-3346.	1.4	19
355	Advances in diagnostic testing. Medical Mycology, 2005, 43, 121-124.	0.3	26
356	Clinical implications of environmental sources forAspergillus. Medical Mycology, 2005, 43, 59-65.	0.3	50
357	Cytokine responses and regulation of interferon-gamma release by human mononuclear cells toAspergillus fumigatusand other filamentous fungi. Medical Mycology, 2005, 43, 613-621.	0.3	58
358	Assessingin vitrocombinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Medical Mycology, 2005, 43, 133-152.	0.3	99
359	Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species. Journal of Clinical Microbiology, 2004, 42, 3475-3482.	1.8	174
360	Detection of the Candida Antigen Mannan in Cerebrospinal Fluid Specimens from Patients Suspected of Having Candida Meningitis. Journal of Clinical Microbiology, 2004, 42, 867-870.	1.8	49

#	Article	IF	Citations
361	Utility of Aspergillus Antigen Detection in Specimens Other than Serum Specimens. Clinical Infectious Diseases, 2004, 39, 1467-1474.	2.9	167
362	In Vitro Interactions between Amphotericin B, Itraconazole, and Flucytosine against 21 Clinical Aspergillus Isolates Determined by Two Drug Interaction Models. Antimicrobial Agents and Chemotherapy, 2004, 48, 2007-2013.	1.4	34
363	Potent Synergistic In Vitro Interaction between Nonantimicrobial Membrane-Active Compounds and Itraconazole against Clinical Isolates of Aspergillus fumigatus Resistant to Itraconazole. Antimicrobial Agents and Chemotherapy, 2004, 48, 1335-1343.	1.4	55
364	Two Patients with Cryptococcal Meningitis and Idiopathic CD4 Lymphopenia: Defective Cytokine Production and Reversal by Recombinant Interferon-Â Therapy. Clinical Infectious Diseases, 2004, 39, e83-e87.	2.9	93
365	Routine Use of a Commercial Test, GLABRATA RTT, for Rapid Identification of Candida glabrata in Six Laboratories. Journal of Clinical Microbiology, 2004, 42, 4870-4872.	1.8	22
366	Effect of pH on the In Vitro Activities of Amphotericin B, Itraconazole, and Flucytosine against Aspergillus Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 3147-3150.	1.4	28
367	Validating PCR for detecting invasive aspergillosis. British Journal of Haematology, 2004, 127, 235-236.	1.2	12
368	Fatal hemorrhagic pneumonia caused by infection due to Kytococcus sedentariusâ€"a pathogen or passenger?. Annals of Hematology, 2004, 83, 447-449.	0.8	23
369	Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infectious Diseases, The, 2004, 4, 349-357.	4.6	449
370	Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection. Lancet, The, 2004, 363, 325-327.	6.3	111
371	Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients. Journal of Medical Microbiology, 2004, 53, 129-134.	0.7	39
372	Antifungal Activity of Nonantifungal Drugs. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 397-407.	1.3	49
373	Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clinical Microbiology and Infection, 2003, 9, 467-474.	2.8	135
374	Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clinical Microbiology and Infection, 2003, 9, 750-753.	2.8	34
375	Culture and infection control. Lancet, The, 2003, 361, 1657.	6.3	1
376	Should we routinely disinfect floors?. Journal of Hospital Infection, 2003, 53, 150.	1.4	4
377	In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates. Antimicrobial Agents and Chemotherapy, 2003, 47, 106-117.	1.4	234
378	Invasive Infections Due to Apophysomyces elegans. Mayo Clinic Proceedings, 2003, 78, 252-253.	1.4	6

#	Article	IF	Citations
379	In vitro activity of amphotericin B, itraconazole, terbinafine and 5-fluocytosine against Exophiala spinifera and evaluation of post-antifungal effects. Medical Mycology, 2003, 41, 301-307.	0.3	20
380	Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media. Journal of Antimicrobial Chemotherapy, 2003, 52, 65-70.	1.3	14
381	Introduction the Forum Report on Advances in the Design of Antifungal Clinical Trials. Clinical Infectious Diseases, 2003, 36, S112-S112.	2.9	0
382	Forum Report: Issues in the Evaluation of Diagnostic Tests, Use of Historical Controls, and Merits of the Current Multicenter Collaborative Groups. Clinical Infectious Diseases, 2003, 36, S123-S127.	2.9	10
383	Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis. Antimicrobial Agents and Chemotherapy, 2003, 47, 3647-3650.	1.4	156
384	Keratitis Caused by Scedosporium apiospermum Successfully Treated with a Cornea Transplant and Voriconazole. Journal of Clinical Microbiology, 2003, 41, 2261-2264.	1.8	68
385	Treatment of Intra-Abdominal Abscesses Caused by Candida albicans with Antifungal Agents and Recombinant Murine Granulocyte Colony-Stimulating Factor. Antimicrobial Agents and Chemotherapy, 2003, 47, 3688-3693.	1.4	8
386	In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera. Journal of Antimicrobial Chemotherapy, 2003, 51, 1297-1300.	1.3	24
387	Aspergillus fumigatusEvades Immune Recognition during Germination through Loss of Tollâ€Like Receptorâ€4â€"Mediated Signal Transduction. Journal of Infectious Diseases, 2003, 188, 320-326.	1.9	290
388	Evaluation of a polymerase chain reaction reverse hybridization line probe assay for the detection and identification of medically important fungi in bronchoalveolar lavage fluids. Medical Mycology, 2003, 41, 65-74.	0.3	10
389	Use of Turbidimetric Growth Curves for Early Determination of Antifungal Drug Resistance of Filamentous Fungi. Journal of Clinical Microbiology, 2003, 41, 4718-4725.	1.8	39
390	Molecular Epidemiology of Aspergillus fumigatus Isolates Recovered from Water, Air, and Patients Shows Two Clusters of Genetically Distinct Strains. Journal of Clinical Microbiology, 2003, 41, 4101-4106.	1.8	131
391	Forum Report: Issues in the Design of Trials of Drugs for the Treatment of Invasive Aspergillosis. Clinical Infectious Diseases, 2003, 36, S113-S116.	2.9	7
392	In vitro susceptibilities of zygomycetes to conventional and new antifungals. Journal of Antimicrobial Chemotherapy, 2003, 51, 45-52.	1.3	299
393	Forum Report: Issues in Clinical Trials of Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients. Clinical Infectious Diseases, 2003, 36, S117-S122.	2.9	54
394	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 576.	1.1	0
395	Cytokine Release in Healthy Donors and Patients with Chronic Granulomatous Disease upon Stimulation with Aspergillus fumigatus. Scandinavian Journal of Infectious Diseases, 2003, 35, 482-487.	1.5	46
396	Cryptococcal meningitis in a child with acute lymphoblastic leukemia. Pediatric Infectious Disease Journal, 2003, 22, 576.	1.1	14

#	Article	IF	Citations
397	Evaluation of a polymerase chain reaction reverse hybridization line probe assay for the detection and identification of medically important fungi in bronchoalveolar lavage fluids. Medical Mycology, 2003, 41, 65-74.	0.3	1
398	Combination Therapy for Keratitis by the Fungus Scedosporium. Cornea, 2003, 22, 92.	0.9	7
399	Preventing fungal infections in chronic granulomatous disease. New England Journal of Medicine, 2003, 349, 1190-1; author reply 1190-1.	13.9	3
400	Comparison of the Etest and the Sensititre Colorimetric Methods with the NCCLS Proposed Standard for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2002, 40, 2876-2885.	1.8	59
401	Nationwide Survey of In Vitro Activities of Itraconazole and Voriconazole against Clinical Aspergillus fumigatus Isolates Cultured between 1945 and 1998. Journal of Clinical Microbiology, 2002, 40, 2648-2650.	1.8	88
402	In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against Scedosporium prolificans. Antimicrobial Agents and Chemotherapy, 2002, 46, 3323-3326.	1.4	41
403	In Vitro Activities of New and Conventional Antifungal Agents against Clinical Scedosporium Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 62-68.	1.4	230
404	Identification of Four Distinct Genotypes of Candida dubliniensis and Detection of Microevolution In Vitro and In Vivo. Journal of Clinical Microbiology, 2002, 40, 556-574.	1.8	77
405	Differentiation of Aspergillus ustus Strains by Random Amplification of Polymorphic DNA. Journal of Clinical Microbiology, 2002, 40, 2231-2233.	1.8	17
406	In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents. Antimicrobial Agents and Chemotherapy, 2002, 46, 2708-2711.	1.4	78
407	Multidrug Resistance inAspergillus fumigatus. New England Journal of Medicine, 2002, 347, 2173-2174.	13.9	77
408	Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis. Antimicrobial Agents and Chemotherapy, 2002, 46, 1953-1959.	1.4	50
409	In vitro susceptibilities of Zygomycota to polyenes. Journal of Antimicrobial Chemotherapy, 2002, 49, 741-744.	1.3	17
410	Comparison of Fractional Inhibitory Concentration Index with Response Surface Modeling for Characterization of In Vitro Interaction of Antifungals against Itraconazole-Susceptible and -Resistant Aspergillus fumigatus Isolates. Antimicrobial Agents and Chemotherapy, 2002, 46, 702-707.	1.4	53
411	In Vitro Interaction of Flucytosine Combined with Amphotericin B or Fluconazole against Thirty-Five Yeast Isolates Determined by both the Fractional Inhibitory Concentration Index and the Response Surface Approach. Antimicrobial Agents and Chemotherapy, 2002, 46, 2982-2989.	1.4	74
412	Method for Measuring Postantifungal Effect in Aspergillus Species. Antimicrobial Agents and Chemotherapy, 2002, 46, 1960-1965.	1.4	24
413	In Vitro Activities of Pentamidine, Pyrimethamine, Trimethoprim, and Sulfonamides against Aspergillus Species. Antimicrobial Agents and Chemotherapy, 2002, 46, 2029-2031.	1.4	23
414	Contamination of Hospital Water withAspergillus fumigatusand Other Molds. Clinical Infectious Diseases, 2002, 34, 1159-1160.	2.9	55

#	Article	IF	Citations
415	Methodological issues related to antifungal drug interaction modelling for filamentous fungi. Reviews in Medical Microbiology, 2002, 13, 101-117.	0.4	13
416	Recent progress in the diagnosis of fungal infections in the immunocompromised host. Drug Resistance Updates, 2002, 5, 3-10.	6.5	34
417	Aspergillus galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. Transplant Infectious Disease, 2002, 4, 64-65.	0.7	18
418	Case Reports. Chronic and acuteAspergillusmeningitis. Mycoses, 2002, 45, 504-511.	1.8	25
419	Case Reports. Chronic and acute Aspergillus meningitis - Falldarstellungen. Chronische und akute Aspergillus-Meningitis. Mycoses, 2002, 45, 504-511.	1.8	26
420	Current Management of Fungal Infections. Drugs, 2001, 61, 13-25.	4.9	80
421	Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. Journal of Hospital Infection, 2001, 47, 143-148.	1.4	95
422	Critical assessment of issues in the diagnosis of invasive aspergillosis. Clinical Microbiology and Infection, 2001, 7, 32-37.	2.8	34
423	Comparison of Spectrophotometric and Visual Readings of NCCLS Method and Evaluation of a Colorimetric Method Based on Reduction of a Soluble Tetrazolium Salt, 2,3-Bis {2-Methoxy-4-Nitro-5-[(Sulfenylamino) Carbonyl]-2H- Tetrazolium-Hydroxide}, for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2001, 39, 4256-4263.	1.8	71
424	Colorimetric Assay for Antifungal Susceptibility Testing of Aspergillus Species. Journal of Clinical Microbiology, 2001, 39, 3402-3408.	1.8	148
425	Involvement of CD14 and Toll-Like Receptors in Activation of Human Monocytes by Aspergillus fumigatus Hyphae. Infection and Immunity, 2001, 69, 2402-2406.	1.0	218
426	Analysis of Growth Characteristics of Filamentous Fungi in Different Nutrient Media. Journal of Clinical Microbiology, 2001, 39, 478-484.	1.8	168
427	Prevention of invasive aspergillosis in AIDS by sulfamethoxazole. Aids, 2001, 15, 1067-1068.	1.0	7
428	Hospital sources of Aspergillus: New routes of transmission?. Revista Iberoamericana De Micologia, 2001, 18, 156-62.	0.4	30
429	Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clinical Microbiology and Infection, 2000, 6, 336-337.	2.8	39
430	In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs. Mycoses, 2000, 43, 309-312.	1.8	28
431	Microbiological diagnosis of invasive fungal infections in transplant recipients. Transplant Infectious Disease, 2000, 2, 80-87.	0.7	39
432	Atypical presentation of Madurella mycetomatis mycetoma in a renal transplant patient. Transplant Infectious Disease, 2000, 2, 96-98.	0.7	21

#	Article	IF	Citations
433	Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 2000, 26, 1131-1132.	1.3	23
434	One-Year Prevalence of Candida dublinienis in a Dutch University Hospital . Journal of Clinical Microbiology, 2000, 38, 3139-3140.	1.8	17
435	Invasive aspergillosis. Medical Mycology, 2000, 38, 215-224.	0.3	19
436	In Vitro Interaction of Terbinafine with Itraconazole against Clinical Isolates of Scedosporium prolificans. Antimicrobial Agents and Chemotherapy, 2000, 44, 470-472.	1.4	105
437	Cervical Spinal Epidural Abscess Due to Group B Streptococcus in a Previously Healthy Elderly Male. Scandinavian Journal of Infectious Diseases, 2000, 32, 577-577.	1.5	7
438	Acremonium strictum Fungaemia in a Paediatric Patient with Acute Leukaemia. Scandinavian Journal of Infectious Diseases, 2000, 32, 442-444.	1.5	33
439	Fungal Contamination of Tobacco and Marijuana. JAMA - Journal of the American Medical Association, 2000, 284, 2875-2875.	3.8	62
440	Clinical applications of non-culture based methods for the diagnosis and management of opportunistic and endemic mycoses. Medical Mycology, 2000, 38, 161-171.	0.3	3
441	Failure To Detect Circulating Aspergillus Markers in a Patient with Chronic Granulomatous Disease and Invasive Aspergillosis. Journal of Clinical Microbiology, 2000, 38, 3900-3901.	1.8	99
442	Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) Methods of In Vitro Susceptibility Testing of Filamentous Fungi and Development of a New Simplified Method. Journal of Clinical Microbiology, 2000, 38, 2949-2954.	1.8	203
443	Candida dubliniensis Candidemia in Patients with Chemotherapy-Induced Neutropenia and Bone Marrow Transplantation. Emerging Infectious Diseases, 1999, 5, 150-153.	2.0	136
444	Comparative study of seven commercial yeast identification systems. Journal of Clinical Pathology, 1999, 52, 271-273.	1.0	67
445	Epidemiology of nosocomial fungal infections: invasive aspergillosis and the environment. Diagnostic Microbiology and Infectious Disease, 1999, 34, 221-227.	0.8	111
446	FAUCET AERATORS: A SOURCE OF PATIENT COLONIZATION WITH STENOTROPHOMONAS MALTOPHILIA. American Journal of Infection Control, 1999, 27, 459-460.	1.1	9
447	Perianal ulcer. Lancet, The, 1999, 353, 1881.	6.3	7
448	Antibacterial activity of hyperforin from St John's wort. Lancet, The, 1999, 354, 777.	6.3	6
449	INVASIVE ASPERGILLOSIS IN TWO PATIENTS WITH PEARSON SYNDROME. Pediatric Infectious Disease Journal, 1999, 18, 739-741.	1.1	13
450	Aspergillus Meningitis: Diagnosis by Non-Culture-Based Microbiological Methods and Management. Journal of Clinical Microbiology, 1999, 37, 1186-1189.	1.8	137

#	Article	IF	Citations
451	Invasive Aspergillosis Caused by Aspergillus ustus : Case Report and Review. Journal of Clinical Microbiology, 1999, 37, 1606-1609.	1.8	76
452	Prevalence of antibodies to Histoplasma capsulatum among dutch speleologists. Journal of Infection, 1998, 37, 200-201.	1.7	0
453	Microgranulomatous Aspergillosis in a Patient with Chronic Granulomatous Disease: Cure with Voriconazole. Clinical Infectious Diseases, 1998, 26, 996-997.	2.9	23
454	Successful Treatment with Voriconazole of Invasive Aspergillosis in Chronic Granulomatous Disease. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1694-1696.	2.5	71
455	Detection of Aspergillus fumigatus PCR products by a microtitre plate based DNA hybridisation assay. Journal of Clinical Pathology, 1998, 51, 617-620.	1.0	18
456	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.. Journal of Antimicrobial Chemotherapy, 1998, 42, 389-392.	1.3	71
457	Resistance of Aspergillus fumigatus to Itraconazole. Scandinavian Journal of Infectious Diseases, 1998, 30, 642-642.	1.5	6
458	Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water. Epidemiology and Infection, 1998, 120, 251-256.	1.0	84
459	Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy, 1998, 42, 873-878.	1.4	101
460	Detection of Antigen in Sera of Patients with Invasive Aspergillosis: Intra- and Interlaboratory Reproducibility. Journal of Clinical Microbiology, 1998, 36, 1612-1616.	1.8	58
461	Diagnostic and Therapeutic Strategies for Invasive Aspergillosis. Seminars in Respiratory and Critical Care Medicine, 1997, 18, 203-215.	0.8	21
462	Needleless Intravenous Systems. Infection Control and Hospital Epidemiology, 1997, 18, 536-537.	1.0	1
463	Pseudo-Outbreak of Multiresistant Pseudomonas aeruginosa in a Hematology Unit. Infection Control and Hospital Epidemiology, 1997, 18, 128-131.	1.0	15
464	Two Strategies for Managing Invasive Aspergillosis: A Decision Analysis. Clinical Infectious Diseases, 1997, 25, 1148-1154.	2.9	51
465	Clostridium septicum sepsis and neutropenic enterocolitis in a patient treated with intensive chemotherapy for acute myeloid leukemia. Annals of Hematology, 1997, 74, 143-147.	0.8	18
466	Serial monitoring ofAspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection, 1997, 25, 86-89.	2.3	80
467	Oral terbinafine for treatment of pulmonaryPseudallescheria boydii infection refractory to itraconazole therapy. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 26-28.	1.3	28
468	Pseudo-Outbreak of Multiresistant Pseudomonas aeruginosa in a Hematology Unit. Infection Control and Hospital Epidemiology, 1997, 18, 128-131.	1.0	13

#	Article	IF	Citations
469	Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. Journal of Clinical Microbiology, 1997, 35, 257-260.	1.8	201
470	Needleless Intravenous Systems. Infection Control and Hospital Epidemiology, 1997, 18, 536-537.	1.0	0
471	Carriage of Staphylococcus haemolyticus among healthcare workers. Journal of Hospital Infection, 1996, 32, 320-321.	1.4	1
472	Prospects for the early diagnosis of invasive aspergillosis in the immunocompromised patient. Reviews in Medical Microbiology, 1996, 7, 105-114.	0.4	27
473	Immunoperoxidase staining for identification of Aspergillus species in routinely processed tissue sections.. Journal of Clinical Pathology, 1996, 49, 798-801.	1.0	47
474	High-Dose Itraconazole for the Treatment of Cerebral Aspergillosis. Clinical Infectious Diseases, 1996, 23, 1196-1197.	2.9	10
475	Genotypic characterization of sequential Aspergillus fumigatus isolates from patients with cystic fibrosis. Journal of Clinical Microbiology, 1996, 34, 2595-2597.	1.8	62
476	Phylogenetic relationships of five species ofAspergillusand related taxa as deduced by comparison of sequences of small subunit ribosomal RNA. Medical Mycology, 1995, 33, 185-190.	0.3	27
477	Clinical evaluation and reproducibility of the Pastorex Aspergillus antigen latex agglutination test for diagnosing invasive aspergillosis.. Journal of Clinical Pathology, 1995, 48, 474-476.	1.0	53
478	Interrepeat Fingerprinting of Third-Generation Cephalosporin-Resistant Enterobacter cloacae Isolated during an Outbreak in a Neonatal Intensive Care Unit. Infection Control and Hospital Epidemiology, 1995, 16, 25-29.	1.0	25
479	Severe Human Psittacosis Requiring Artificial Ventilation: Case Report and Review. Clinical Infectious Diseases, 1995, 20, 440-442.	2.9	41
480	Septic shock caused by group G Î²-haemolytic streptococci as presenting symptom of acute myeloid leukaemia. Netherlands Journal of Medicine, 1995, 46, 153-155.	0.6	12
481	Interrepeat Fingerprinting of Third-Generation Cephalosporin-Resistant Enterobacter cloacae Isolated during an Outbreak in a Neonatal Intensive Care Unit. Infection Control and Hospital Epidemiology, 1995, 16, 25-29.	1.0	20
482	Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. Journal of Clinical Microbiology, 1995, 33, 3150-3153.	1.8	157
483	Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. Journal of Clinical Microbiology, 1995, 33, 1912-1914.	1.8	181
484	Endophthalmitis as presenting symptom of group G streptococcal endocarditis. Infection, 1994, 22, 56-57.	2.3	19
485	Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection, 1994, 22, 81-85.	2.3	54
486	Polymerase chain reaction as a diagnostic tool for invasive aspergillosis: evaluation in bronchoalveolar lavage fluid from low risk patients. Serodiagnosis and Immunotherapy in Infectious Disease, 1994, 6, 203-208.	0.2	15

#	Article	IF	Citations
487	COLONIZATION OF THE FEMALE GENITAL TRACT WITH HAEMOPHILUS INFLUENZAE. Pediatric Infectious Disease Journal, 1994, 13, 758.	1.1	1
488	General primer-mediated PCR for detection of Aspergillus species. Journal of Clinical Microbiology, 1994, 32, 1710-1717.	1.8	181
489	CROSS-INFECTION WITH PSEUDOMONAS AERUGINOSA IN A NEONATAL INTENSIVE CARE UNIT CHARACTERIZED BY POLYMERASE CHAIN REACTION FINGERPRINTING. Pediatric Infectious Disease Journal, 1993, 12, 1027-1028.	1.1	12
490	Hygiene, skin infections and types of water supply in Venda, South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 681-684.	0.7	17
491	Galactomannan and Anti-Aspergillus Antibody Detection for the Diagnosis of Invasive Aspergillosis. , 0, , 363-372.		3